IMV Inc.

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV develops T cell-activating cancer immunotherapies and other vaccine candidates based on DepoVax™, the company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. IMV has advanced two T cell-activating therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing its lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The company is also exploring additional applications of DepoVax, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. IMV also has ongoing clinical projects to assess the potential of DepoVax to address malaria and the Zika virus.

Expert Comments:

Management Q&A: View From the Top
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients.
read more >
André Uddin, Mackie Research Capital (5/14/18)
"IMV Inc. reported Q1/18 revenues of $0.1M compared to $0M last year versus our estimate of $0M. . .as of Q1/18E, the company had $24M in cash, which should be sufficient to fund the corporate operations (including clinical trials) through Q4/19. . .we are maintaining our Speculative Buy rating and our target price of CA$8.70."

Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news.
read more >
André Uddin, Mackie Research Capital (5/3/18)
"Immunovaccine Inc. announced it has applied to list on NASDAQ; concurrent with the application, the company has conducted a 3.2:1 reverse stock split. We are maintaining our Speculative Buy rating and changing our target price to CA$8.70 to account for the reverse share split."

Douglas Loe, Echelon Wealth Partners (5/3/18)
"Nova Scotia-based immune therapy developer Immunovaccine Inc. (hereafter called IMV Inc.) is revising its capital structure next week through a 3.2:1 share consolidation that will bring basic shares outstanding from 137.4M to 42.9M. . .the company also intends to list on the NASDAQ exchange later in Q2/18."

Douglas Loe, Echelon Wealth Partners (4/24/18)
"Nova Scotia-based immune therapy developer Immunovaccine Inc. expanded its collaboration with epacadostat developer Incyte this morning, adding an extra layer of clinical activity to an already ongoing, 40-patient, Phase 1/2 recurrent ovarian cancer trial by initiating a similarly sized, Phase 2, 32-patient, open-label but controlled trial targeting the same indication. . .we assume that enrollment could commence as early as Q2/18 and generate interim data as early as H1/19."

Douglas Loe, Echelon Wealth Partners (4/16/18)
"Nova Scotia-based immune therapy developer Immunovaccine Inc. is presenting preclinical data at the American Association for Cancer Research meeting in Chicago this week, specifically featuring its DepoVax-neoepitope program, its Incyte-partnered DepoVax-survivin program and its Dana Farber Cancer Institute-partnered DepoVax-HPV16 E7 program. Two of these DPX formulations are already advancing well in Phase 2 clinical studies (DPX-Survivac, DPX-E7)."

Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status.
read more >
Douglas Loe, Echelon Wealth Partners (4/3/18)
"As in Q4/17 and again in Q1/18, we are ascribing Top Pick status to Nova Scotia-based immune therapy formulation developer Immunovaccine Inc., while maintaining our Speculative Buy rating and $3.25 price target on the stock. The stock is cumulatively up 68% since end of September 2017, when we originally ascribed Top Pick status to the stock. . .cumulative return since we initiated on the company in September 2016 is 164%."

Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well.
read more >
Douglas Loe, an analyst with Echelon Partners, outlined the reasons this biotech deserves Top Pick status.
read more >
This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts.
read more >

More Expert Comments

Experts Following This Company

Endri Leno, Equity Analyst – National Bank of Canada
Douglas Loe, Analyst – Echelon Wealth Partners
André Uddin – Mackie Research Capital

The information provided above is from analysts, newsletters, the company and other contributors.

IMV Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
Unique Delivery Platform
Unique target (survivin) in Immuno-Oncology for T Cell activation
Multiple clinical milestones between now and the end of 2018
catalyst Calendar